Investor Alert

Market Pulse Archives

Nov. 19, 2021, 8:30 a.m. EST

Moderna COVID-19 vaccine booster gets FDA OK for all adults

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Share of Moderna Inc. /zigman2/quotes/205619834/composite MRNA -4.45% shot up 6.0% in premarket trading Friday, after the biotechnology company said the U.S. Food and Drug Administration has extended the emergency use authorization (EUA) of a booster dose of its COVID-19 vaccine to all adults, aged 18 and older. The booster dose is for those who have completed COVID-19 vaccinations, with any authorized or approved vaccine, at least six months ago. "This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country," said Moderna Chief Executive Stéphane Bancel. Next, an advisory committee of the U.S. Centers for Disease Control and Prevention (CDC) will meet to discuss a potential recommendation for rolling out COVID-19 boosters. Moderna's stock has tumbled 33.1% over the past three months through Thursday but has soared 140.7% year to date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.89% has gained 25.3% this year.

US : U.S.: Nasdaq
$ 160.07
-7.45 -4.45%
Volume: 11.80M
Jan. 21, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$64.90 billion
Rev. per Employee
-84.79 -1.89%
Volume: 3.20B
Jan. 21, 2022 4:52p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.